Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Correction for Robbesyn et al., Arterioscler Thromb Vasc Biol 25 (6) 1206-1212.
Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:e128

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:e128.)
© 2005 American Heart Association, Inc.

Correction


An extract of the first 100% of the full text is provided, because this article has no abstract.
 

In the June 2005 issue of Arteriosclerosis, Thrombosis, and Vascular Biology, in the article by Robbesyn et al (Arterioscler Thromb Vasc Biol. 2005:25:1206–1212.), EGF was incorrectly spelled out in the title, abstract, and introduction as "endothelial growth factor."

The abbreviation should have been expanded as "epidermal growth factor." The publisher regrets this error.




This article has been cited by other articles:


Home page
Pharmacol. Rev.Home page
A. Kontush and M. J. Chapman
Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis
Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374.
[Abstract] [Full Text] [PDF]